Finding new ways to treat triple-negative breast cancer that resists carboplatin
Circumventing acquired carboplatin resistance in triple-negative breast cancers
This study is looking for new ways to treat triple-negative breast cancer that no longer responds to the common chemotherapy drug carboplatin, by testing different combinations of treatments to find out what works best for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10878965 on NIH RePORTER |
What this research studies
This research aims to discover new treatment strategies for triple-negative breast cancer (TNBC) that has become resistant to carboplatin, a common chemotherapy drug. The researchers will investigate biological pathways that can be targeted alongside existing treatments to promote cancer cell death. By using patient-derived xenograft models, they will test combinations of drugs to see which are most effective against resistant cancer cells. The ultimate goal is to translate these findings into clinical options for patients suffering from metastatic TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have shown resistance to carboplatin treatment.
Not a fit: Patients with non-triple-negative breast cancer or those who have not undergone carboplatin treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with carboplatin-resistant triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting similar biological pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Harrell, Joshua (Chuck) — Virginia Commonwealth University
- Study coordinator: Harrell, Joshua (Chuck)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.